Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

Soleno Therapeutics, Inc. (SLNO) is identified as a strong momentum play, boasting a Zacks Momentum Style Score of 'A' and a #2 (Buy) Rank. The company has demonstrated significant outperformance against its industry and the S&P 500, including an 87.5% gain over the past year. This strong price action is complemented by positive earnings estimate revisions, with the full-year consensus improving from -$3.09 to -$2.33 in 60 days, reinforcing its potential as a near-term outperformer.

Analysis

Soleno Therapeutics, Inc. (SLNO) exhibits strong momentum characteristics, supported by both significant price outperformance and positive analyst revisions. The stock has gained 87.5% over the past year, substantially outperforming the S&P 500's 18.63% return. This relative strength is also evident in the short term, with a 6.91% gain in the past week while its industry, Medical - Drugs, declined by 0.38%. This price action is supported by fundamental developments, specifically upward earnings estimate revisions. Over the last 60 days, the consensus full-year EPS estimate has improved from -$3.09 to -$2.33, based on three upward revisions and no downward revisions. This positive revision trend also applies to the next fiscal year. These factors culminate in a Zacks Rank of #2 (Buy) and a Momentum Style Score of 'A', positioning the stock as a candidate for near-term outperformance according to the source's methodology.

Key Decisions for Investors

• For investors with a momentum-driven strategy, SLNO presents a strong case for a long position, given its significant outperformance against its industry and the broader market, coupled with a top-tier Momentum Score of 'A'.
• The positive trend in earnings estimate revisions, which improved the full-year consensus loss per share from -$3.09 to -$2.33, provides a fundamental basis for the rally, suggesting investors should monitor for continued upward revisions as a key catalyst.
• While the outlook is positive, investors should be mindful that momentum stocks can be volatile; therefore, it is prudent to consider the stock's high recent gains and manage risk accordingly, potentially by monitoring its 20-day average trading volume for signs of trend confirmation or reversal.